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Abstract
Guanylyl cyclase activating protein 1 (GCAP1), a member of the neuronal calcium sensor (NCS) subclass of the
calmodulin superfamily, confers Ca2+-sensitive activation of retinal guanylyl cyclase 1 (RetGC1) upon light activation
of photoreceptor cells. Here we present NMR assignments and functional analysis to probe Ca2+-dependent
structural changes in GCAP1 that control activation of RetGC. NMR assignments were obtained for both the Ca2+-
saturated inhibitory state of GCAP1 versus a GCAP1 mutant (D144N/D148G, called EF4mut), which lacks Ca2+
binding in EF-hand 4 and models the Ca2+-free/Mg2+-bound activator state of GCAP1. NMR chemical shifts of
backbone resonances for Ca2+-saturated wild type GCAP1 are overall similar to those of EF4mut, suggesting a
similar main chain structure for assigned residues in both the Ca2+-free activator and Ca2+-bound inhibitor states. This
contrasts with large Ca2+-induced chemical shift differences and hence dramatic structural changes seen for other
NCS proteins including recoverin and NCS-1. The largest chemical shift differences between GCAP1 and EF4mut
are seen for residues in EF4 (S141, K142, V145, N146, G147, G149, E150, L153, E154, M157, E158, Q161, L166),
but mutagenesis of EF4 residues (F140A, K142D, L153R, L166R) had little effect on RetGC1 activation. A few
GCAP1 residues in EF-hand 1 (K23, T27, G32) also show large chemical shift differences, and two of the mutations
(K23D and G32N) each decrease the activation of RetGC, consistent with a functional conformational change in EF1.
GCAP1 residues at the domain interface (V77, A78, L82) have NMR resonances that are exchange broadened,
suggesting these residues may be conformationally dynamic, consistent with previous studies showing these
residues are in a region essential for activating RetGC1.
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Introduction
Guanylyl cyclase activating proteins (GCAPs) belong to the
neuronal calcium sensor (NCS) branch of the calmodulin
superfamily [1–3] and regulate Ca2+-sensitive activity of retinal
guanylyl cyclase (RetGC) in rod and cone cells [4–6].
Phototransduction in retinal rods and cones is modulated by
intracellular Ca2+ sensed by GCAPs [7,8] and defects in Ca2+
signaling by GCAPs are linked to retinal diseases [9]. Light
excitation of photoreceptor cells triggers a phototransduction
cascade that causes hydrolysis of cGMP and hence closure of
cGMP-gated channels [10]. Light-activated channel closure
blocks the entry of Ca2+, which lowers the cytosolic Ca2+
concentration from ~250-500 nM in the dark down to ~25 nM in
the light [11]. This drop in Ca2+ causes the change in formation
of Ca2+-free/Mg2+-bound GCAPs that activate RetGC [12],
whereas Ca2+-bound GCAPs inhibit RetGC at high Ca2+ levels
maintained in the dark [13–15].
The GCAPs (GCAP1 [6], GCAP2 [16], GCAP3 [17] and
GCAP4-8 [18]) are all ~200-amino acid residue proteins
containing a covalently attached N-terminal myristoyl group
and four EF-hand motifs (EF1 through EF4, Figure 1). Mg2+
binds to three EF-hands (EF2, EF3 and EF4) when cytosolic
Ca2+ levels are low and Mg2+-bound GCAP1 activates RetGC,
preferentially its RetGC1 isozyme [12,19,20]. The X-ray crystal
structure of Ca2+-bound GCAP1 [21] and NMR structure of
GCAP2 [22] showed that the four EF-hands form two semi-
globular domains (EF1 and EF2 in the N-domain, and EF3 and
EF4 in the C-domain); Ca2+ is bound at EF2, EF3 and EF4; and
the N-terminal myristoyl group in GCAP1 is buried inside the
Ca2+-bound protein, flanked by hydrophobic residues at the N-
and C-termini (see italicized residues in Figure 1). The
structure of the physiological activator form of GCAPs (Mg2+-
bound/Ca2+-free state) is currently unknown.
Recoverin is the only NCS protein whose structure is known
in both the Ca2+-free and Ca2+-bound states (Figure 1) [23,24].
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Ca2+-free recoverin contains a myristoyl group sequestered
inside the protein that interacts intimately with residues from
EF1, EF2 and EF3 [25,26]. Ca2+ binding at EF2 and EF3 leads
to a 45°-swiveling of the two domains in recoverin that
promotes extrusion of the fatty acyl group outward (termed
Ca2+-myristoyl switch), enabling it to interact with membrane
targets [23,27]. Previously, we have shown that GCAP1 does
not possess a Ca2+-myristoyl switch because the attached
myristoyl group in GCAP1 remains sequestered in both the
Ca2+-free/Mg2+-bound and Ca2+-bound states [28]. However, we
wondered if GCAP1 might undergo a Ca2+-induced
rearrangement at the domain interface like what is seen for
both recoverin [23] and NCS-1 [29]. Here, we present NMR
and mutagenesis functional analysis on GCAP1 to probe
structural changes between the Ca2+-saturated inhibitory state
versus a GCAP1 mutant (D144N/D148G, called EF4mut),
which contains Ca2+ bound at EF2 and EF3, but lacks Ca2+ at
EF4 and was shown to serve as a functional mimic of GCAP1
in the Ca2+-free/Mg2+-bound activator state [12]. Our results
indicate that EF4mut (activator) and Ca2+-saturated GCAP1
(inhibitor) have fairly similar backbone NMR chemical shifts.
The largest chemical shift differences are seen for residues in
EF4 and a few residues in EF1 (K23, T27 and G32). GCAP1
residues at the interface between EF2 and EF3 (V77, A78, L82
and W94) have broadened NMR resonances, indicating these
residues are conformationally flexible in both activator and
inhibitor states.
Results
NMR assignments for GCAP1 activator mutant
(EF4mut)
NMR spectroscopy was used to probe Ca2+-induced protein
conformational changes in GCAP1 by examining 15N-1H HSQC
spectra of Ca2+-saturated wildtype protein (Figure 2A) and
comparing it to that of the EF4mut activator state (Figure 2B).
The EF4mut sample with Ca2+ bound at EF2 and EF3 (and no
Ca2+ bound at EF4) was shown previously to activate RetGC
and therefore serves as a functional mimic of the Ca2+-free/
Mg2+-bound activator state [12]. The EF4mut sample was used
rather than the wildtype Ca2+-free/Mg2+-bound activator state,
because EF4mut is more soluble and stable under conditions
for NMR (the Ca2+-free/Mg2+-bound wildtype protein tends to
aggregate under NMR conditions, whereas EF4mut does not).
Ca2+ binding to EF2 and EF3 in EF4mut activator state
increases the folding stability that allows the protein to remain
Figure 1.  Amino acid sequence alignment of GCAP1 with various NCS proteins.  Secondary structural elements are indicated
schematically. The four EF-hands (EF1, EF2, EF3 and EF4) are underlined. Residues mutated in EF4mut (D144N/D148G) are
indicated in red. Residues at the domain interface (V77 – L97) that have broadened NMR resonances are shown in italics.
doi: 10.1371/journal.pone.0081822.g001
Conformation of GCAP1 Activator State
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folded in NMR experiments performed at elevated
temperatures (37 °C), which was necessary to achieve
improved spectral quality. Although the NMR spectrum of
EF4mut (with Ca2+ bound at EF2 and EF3) is much improved
compared to that of Ca2+-free/Mg2+-bound wildtype, EF4mut still
has somewhat broadened NMR peaks compared to what is
expected for a monomeric protein at 23 kDa, suggesting that
EF4mut might form a dimer under NMR conditions.
To verify whether GCAP1 forms a dimer in our NMR
experiments, the rotational correlation time (τc) of the protein
was measured by 15N NMR relaxation analysis (Figure 3). The
longitudinal and transverse 15N NMR relaxation rates (R1 and
R2) for each assigned amide resonance of EF4mut are shown
in Figure 3. The average 15N R1 and R2 values from residues in
structured regions are 0.84 (± 0.04) s-1 and 28 (± 0.5) s-1,
respectively. Assuming isotropic tumbling, the average
rotational correlation time obtained from R1/R2 ratios of all
residues within 1 standard deviation of the average value [30]
was calculated to be 22 ±1 ns at 37 °C, consistent with an
average molar mass of 36 ±5 kDa, which is considerably higher
than the calculated mass of a protein monomer (23 kDa). In
addition, size-exclusion chromatography analysis performed at
high concentration of GCAP1 (Figure 3C) indicated that Ca2+-
saturated wildtype GCAP1 has elution volume consistent with a
molar mass of 40 ±4 kDa. EF4mut has the same elution
volume as wildtype (not shown). Thus, both size-exclusion
chromatography and NMR relaxation data suggest that Ca2+-
saturated GCAP1 and EF4mut are at least partially dimeric
under NMR conditions.
The peaks in the 1H-15N HSQC NMR spectrum of GCAP1
(Figure 2) represent main chain and side-chain amide groups
that provide a residue-specific fingerprint of the overall protein
conformation. The resonance assignments for Ca2+-saturated
GCAP1 were reported previously [31]. The NMR assignments
for EF4mut were determined in this study as described in
Methods. Because EF4mut forms a dimer under NMR
conditions (Figure 3), the peak broadening due to dimerization
caused a significant decrease in the signal-to-noise ratio and
prevented detection of at least 25% of expected backbone
resonances in three-dimensional NMR experiments. Therefore,
backbone assignments were obtained for ~70% of the residues
in EF4mut compared with ~85% assignment for Ca2+-saturated
GCAP1 [31]. The unassigned residues for EF4mut (due to
peak broadening) include the first 10 residues from the N-
terminus, part of the exiting helix of EF2 (residues M74 – A79),
domain linker (residues S81 – Q90), entering helix of EF3
(residues K91 – Y99), linker between EF3 and EF4 (residues
N123 – M130), and part of the C-terminal helix adjacent to EF4
(residues L170 – D175). The broadening of these unassigned
resonances in EF4mut suggests these regions in the activator
state are conformationally dynamic.
Downfield shifted NMR peaks at ~10.5 ppm for GCAP1
(inset, Figure 2) are assigned to conserved glycine residues in
the EF-hand Ca2+-binding loops and are characteristic of Ca2+
bound EF-hands. In Ca2+-saturated GCAP1 (Figure 2A), three
downfield peaks assigned to G69 (EF2), G105 (EF3) and G149
(EF4) confirm that Ca2+ is bound at EF2, EF3 and EF4 as seen
in the crystal structure [21]. In EF4mut (Figure 2B), two
downfield peaks assigned to G69 (EF2) and G105 (EF3)
confirm that Ca2+ is bound at EF2 and EF3 (and not EF4) as
seen by fluorescence spectroscopy of the mutants [12,19].
Thus, the binding of Ca2+ at EF4 in GCAP1 is critical for
switching between the activator and inhibitor conformational
states.
Mapping chemical shift changes in activator vs
inhibitor forms of GCAP1
The NMR chemical shift assignments in Figure 2 were used
to calculate the chemical shift difference (CSD = {(HNA – HNI)2 +
(15NA –15NI)2}1/2) for activator vs inhibitor forms of GCAP1 plotted
as a function of residue in Figure 4A (where HNA and 15NA are
amide 1H and 15N chemical shifts in the activator state, and HNI
and 15NI are amide 1H and 15N chemical shifts in the inhibitor
state). The average CSD value calculated from all assigned
residues in GCAP1 (CSDave = 0.14 ppm) is 10-fold lower than
that calculated for the two conformational states of recoverin’s
Ca2+-myristoyl switch [23]. The relatively low CSDave is
consistent with GCAP1 having a fairly similar main chain
topology (for the assigned residues) in both EF4mut activator
and Ca2+-saturated inhibitor states. The small structural change
for the two states of GCAP1 is in stark contrast to the profound
structural differences between the two conformational states of
recoverin’s Ca2+-myristoyl switch [32,33]. The myristoyl group
of recoverin is buried inside the protein in the Ca2+-free state,
and Ca2+-binding to recoverin promotes extrusion of the
myristoyl group with a concomitant change in protein structure
[23]. By contrast for GCAP1, the attached myristoyl group is
sequestered inside the protein in Ca2+-free, Ca2+-free/Mg2+-
bound and Ca2+-saturated states [28], consistent with our
finding that the overall main chain structure of GCAP1 remains
similar for both the EF4mut activator and Ca2+-saturated
inhibitor forms.
The GCAP1 residues having largest CSD values are found in
EF4 (S141, K142, V145, N146, G147, G149, E150, L153,
E154, M157, E158, Q161, L166) and highlighted red in Figure
4B. The relatively large CSD values for residues in EF4 are
explained in part by the absence of a bound Ca2+ at EF4 in
EF4mut (in contrast to Ca2+ bound at EF4 in Ca2+-saturated
wildtype), which causes a change in the local charge
environment in EF4. Therefore, large CSD values for residues
in EF4 indicate a local main chain conformational change in
EF4 due to Ca2+ binding at this site. However, mutagenesis of
EF4 residues (F140A, K142D, L153R, L166R) shows almost
no effect on cyclase activation (Table 1), suggesting these
residues do not interact directly with RetGC1. We conclude that
single mutations of EF4 residues having a relatively large CSD
(F140A, K142D, L153R, L166R) are not sufficient to prevent
Ca2+-induced conformational changes in EF4.
A few residues in EF1 (K23, T27, G32) have relatively high
CSD values (Figure 4B), consistent with a structural change in
EF1 even though EF1 does not bind Ca2+. Mutagenesis of
some of these EF1 residues (K23D, G32N) caused a strong
decrease in the ability of GCAP1 to activate cyclase with more
than 10-fold decrease in binding affinity to the cyclase (Table 1
and Figure 5). However, there was no obvious correlation
between the magnitude of the CSD and their importance for
Conformation of GCAP1 Activator State
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Figure 2.  NMR spectra of activator vs. inhibitor forms of GCAP1.  Two-dimensional (1H-15N HSQC) NMR spectra of 15N-labeled
wildtype Ca2+-saturated GCAP1 (A) and EF4mut (B). Spectra were obtained at 37 °C in the presence of 40 mM octylglucoside.
Downfield resonances (~10.5 ppm) are assigned to conserved glycine residues in each Ca2+-bound EF-hand loop. For Ca2+-
saturated GCAP1 (A), downfield peaks assigned to G69, G105 and G149 indicate Ca2+ is bound at EF2, EF3 and EF4. For EF4mut
(B), downfield peaks assigned to G69 and G105 indicate Ca2+ is bound at EF2 and EF3 in EF4mut. Sequence specific resonance
assignments for Ca2+-saturated GCAP1 were determined previously [31].
doi: 10.1371/journal.pone.0081822.g002
Conformation of GCAP1 Activator State
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RetGC activation, because substitutions of T27 did not strongly
affect activation of RetGC1. Nonetheless, the detected change
in structural environment for some EF1 residues (K23, G32)
would be consistent with EF1 undergoing a functional
conformational change related to its activator state. The drastic
decrease in apparent affinity of GCAP1 for RetGC1 caused by
substitutions of K23 and G32 compared to that of wildtype
GCAP1 argues that these EF1 residues are located at or near
the RetGC binding site of GCAP, consistent with observations
from previous mutagenesis studies [34,35]. Our use of GCAP1
and RetGC1 from different mammalian species should not
affect the interpretation of the functional data, because
mammalian GCAP1 homologs are nearly identical, use the
Figure 3.  GCAP1 forms a dimer in solution.  15N NMR relaxation data are shown for EF4mut. Spin-lattice relaxation rate
constants (A) and spin-spin relaxation rate constants (B) are plotted as a function of residue number. All data were measured at
60.81 MHz 15N frequency and 37 °C. (C) Size-exclusion chromatography (SEC) elution profiles are shown for GCAP1 wildtype (solid
line) and V77E (dotted line). The protein concentration was 200 μM for the samples analyzed by SEC.
doi: 10.1371/journal.pone.0081822.g003
Conformation of GCAP1 Activator State
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same regulatory mechanisms, and work across different
mammalian species in transgenic models [11,36–38].
Residues at the GCAP1 domain interface have broad
NMR resonances
The crystal structure of GCAP1 [21] contains two globular
domains (N-domain: EF1 and EF2 and C-domain: EF3 and
EF4) that form contacts involving residues in EF2 and EF3,
called the domain interface. Residues at the GCAP1 domain
Figure 4.  NMR chemical shift mapping for GCAP1.  (A) Amide chemical shift differences between EF4mut and Ca2+-saturated
wildtype (CSD = {(HNA – HNI)2 + (15NA – 15NI)2}1/2 , where “A” and “I” designate activator and inhibitor states) plotted as a function of
residue number. (B) CSD values from part “A” are mapped onto the GCAP1 crystal structure (2R2I). Residues with the largest
chemical shift difference (CSD > 0.12 ppm) are highlighted in red, intermediate chemical shift differences (0.06 < CSD < 0.12)
shown in yellow, and smallest chemical shift differences (CSD < 0.06) shown in green. Unassigned residues are colored gray and
the myristoyl group is orange.
doi: 10.1371/journal.pone.0081822.g004
Conformation of GCAP1 Activator State
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interface (V77, A78, L82, W94, L98) and domain linker
(residues S81 - Q90) have not been assigned in Figure 4A
because their backbone resonances are broadened beyond
detection. The broadening of these resonances is likely caused
by exchange dynamics on the chemical shift time scale.
Indeed, the corresponding residues in recoverin have been
shown to undergo millisecond exchange dynamics [39] and
recoverin’s domain interface region (exiting helix of EF2 and
entering helix of EF3) is conformationally dynamic [40]. The
millisecond dynamics of the domain interface in recoverin is a
consequence of the Ca2+-induced domain swiveling that alters
the interface between EF2 and EF3 [23]. We suggest that a
similar conformational change (that alters contacts between
EF2 and EF3) may also take place in GCAP1, but with perhaps
a smaller overall displacement of the two domains.
Unlike recoverin that switches between stably folded Ca2+-
free and Ca2+-bound conformational states, the tertiary
structure of Ca2+-free/Mg2+-free GCAP1 forms a molten globule-
like state [28], despite preserving most of its secondary
structure [41]. Consequently, the apo form of GCAP1 is
physiologically inactive [12,19,42]. Instead, GCAP1 always
contains metal (Mg2+ or Ca2+) bound at EF2 and EF3 in the
activator state, and Ca2+ binding at EF4 causes a functional
transition to the inhibitor state [43]. To gain some insight into a
possible conformational change in GCAP1 due to Ca2+ binding
at EF4, we constructed a homology model for the EF4mut
activator state (Ca2+ bound at EF2 and EF3) based on the
known structure of recoverin that contains Ca2+ bound at EF2
and EF3 [23] (see Figure 6). The N-domain in the homology
model (extruded myristoyl group) was replaced by the N-
domain from the GCAP1 crystal structure (sequestered
myristoyl group). In this structural model of EF4mut (with
sequestered myristoyl group and Ca2+ bound at EF2 and EF3),
the domain interface consists of residues in the exiting helix of
EF2 (V77, A78 and L82) that are mostly solvent exposed and
make contacts with residues in the entering helix of EF3 (W94
and L98). The modeled structure of EF4mut at the domain
interface (Figure 6A) is similar to what is seen in the GCAP1
crystal structure (Ca2+-saturated inhibitor state, Figure 6B).
However, a unique structural feature of EF4mut can be seen in
the entering helix of EF3 that is shortened by a half turn, which
alters the orientation of the W94 side-chain. In EF4mut (Figure
6A), the W94 indole ring points downward below L82, whereas
the indole group points upward above L82 in the GCAP1
crystal structure (Figure 6B). The rearrangement of the W94
indole side-chain at the domain interface in activator vs
inhibitor states of GCAP1 would kinetically alter the chemical
shift environment in this region and might help explain the
observed broadening of NMR resonances for V77, A78, L82
and W94.
If a conformational change at the domain interface is
functionally relevant and directly controls cyclase activation,
then one would expect specific mutations at the interface to
have functional effects. We constructed single mutants of
residues at the domain interface (V77E, L82E and W94F) that
exhibit exchange broadened NMR resonances. Quite strikingly,
we find that each one of these mutants of GCAP1 has lost the
ability to activate RetGC (Table 1). Each mutant was verified by
NMR to remain structurally intact as evidenced by the spectral
similarity for residues in structured regions (Figure 5A), but
Table 1. Mutagenesis of GCAP1 residues with high CSD values.
Amino Acid CSD1 Mutation RetGC1 Amax 2 (nmol cGMP/mg/min) GC1 Affinity2, K1/2 (μM)
  Wild type 29.1 ±0.7 (N=2) 1.7 ±0.06
K23 0.06 D23 8.7 ±0.6 (N=2) 25 ±3
T27 0.16 E27 28.4 ±0.4 (N=2) 2.9 ±0.1
G32 0.14 N32 13.6 ±0.6 (N=2) 40 ±6.5
F43 0.06 A43 28.2 ±1.2 (N=2) 1.2 ±0.1
V77 NA4 E77 ND3 (N=3) ND (N=3)
A78 NA E78 ND (N=3) ND (N=3)
L82 NA E82 ND (N=2) ND (N=2)
W94 NA F94 15.1 ±0.7 (N=2) 7.3 ±1.1
I115 0.15 W115 25.6 ±0.6 (N=2) 2.4 ±0.1
F140 0.21 A140 29.5 ±0.4 (N=2) 1.7 ±0.02
K142 0.26 D142 27.8 ±0.6 (N=2) 1.3 ±0.03
S152 0.29 E152 20.3 ±0.5 (N=2) 7.3 ±0.9
L153 0.16 R153 27.4 ±0.1 (N=2) 3.2 ±0.07
L166 0.12 R166 27.6 ±0.5 (N=2) 3.9 ±0.2
1. Chemical shift difference (CSD) from values plotted in Figure 4A.
2. RetGC activity and apparent affinity for GCAP1 (mean±SD) determined as described in Methods.
3. ND: non-detectable.
4. NA: not assigned due to exchange broadening.
doi: 10.1371/journal.pone.0081822.t001
Conformation of GCAP1 Activator State
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interestingly, the V77E mutant (unlike wildtype) is monomeric
even at high protein concentrations used for NMR (Figure 3C).
The three downfield NMR resonances (at ~10.5 ppm in Figure
5B) for each mutant (V77E, L82E and W94A) show that Ca2+ is
Figure 5.  Structural characterization of GCAP1 mutants at the domain interface.  (A) Overlay of 15N-1H HSQC spectra of V77E
(red), L82E (blue), WT (black) and W94F (green) indicate that each mutant is properly folded and structurally intact. The mutant
spectra look similar to that of wildtype particularly for residues in structured regions. Minor spectral differences are observed for
exposed residues in unstructured regions, most likely due to small differences in solvent conditions. (B) Expanded view of 15N-1H
HSQC downfield region for GCAP1 mutants: V77E (red), L82E (blue), WT (black) and W94F (green). Three downfield NMR peaks
assigned to G69, G105 and G149 indicate Ca2+ is bound functionally at EF2, EF3 and EF4 for each mutant.
doi: 10.1371/journal.pone.0081822.g005
Conformation of GCAP1 Activator State
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bound at EF2, EF3 and EF4, and that each mutant retains
functional Ca2+ binding. Therefore, the lack of cyclase
activation by these mutants is not due to protein misfolding.
Our NMR and mutagenesis results demonstrate that residues
at the domain interface in GCAP1 are conformationally
dynamic, essential for activation of RetGC, and at least one
(V77) is required for GCAP1 dimerization.
Discussion
NCS proteins like recoverin and NCS-1 undergo large Ca2+-
induced conformational changes that cause extrusion of the N-
terminal myristoyl group, termed Ca2+-myristoyl switch
[23,29,40]. A major difference in the structural dynamics
between the different NCS proteins is the lack of a Ca2+-
myristoyl switch in GCAP proteins [28,44,45], and different
structural roles for myristoylation and metal binding to control
membrane targeting [46,47]. Although crystal structures are
known for Ca2+-bound GCAPs [21], little is known structurally
about the Mg2+-bound/Ca2+-free activator state of GCAPs and
how Ca2+-induced conformational changes in GCAPs control
cyclase activation.
In this study, we present NMR assignments and
mutagenesis data for GCAP1 to probe Ca2+-dependent
conformational changes between the Ca2+-saturated inhibitory
state versus the EF4mut activator state that contains Ca2+
bound at EF2 and EF3 (Figure 2) which mimics the activator
state [12]. Overall, the NMR chemical shift differences between
Ca2+-saturated wild type GCAP1 and EF4mut are relatively
small (Figure 4), suggesting a similar overall main chain
conformation for the two conformational states of GCAP1. This
is in a sharp contrast to large Ca2+-induced conformational
changes seen for the corresponding residues in other NCS
proteins, including recoverin [23] and NCS-1 [29]. NMR
relaxation data and size-exclusion chromatography analysis
indicate that Ca2+-saturated GCAP1 and EF4mut (with Ca2+-
bound at EF2 and EF3) are both dimeric in solution under NMR
conditions (Figure 3). A GCAP1 homolog, GCAP2 undergoes a
Ca2+-sensitive dimerization at micromolar protein
concentrations, which originally suggested that reversible
dimerization may control formation and activation of
RetGC:GCAP in a 2:2 complex [35,48]. Although dimerization
of GCAP1 observed in this study (at high protein concentration)
does not appear to be Ca2+ sensitive, it is possible that GCAP1
dimerization might promote a functional interaction within a
RetGC1 dimer on the disk membrane [49,50]. The binding
stoichiometry of the GCAP1:RetGC1 complex has been
estimated to be equimolar [51], consistent with a complex that
contains a RetGC1 dimer bound to two molecules of GCAP1.
We show in this study that a GCAP1 mutation (V77E) that
eliminates GCAP1 dimerization (Figure 3C) also abolishes its
ability to activate RetGC (Table 1). However, it is not clear
whether the V77E mutation in GCAP1 disrupts its primary
binding to RetGC or prevents secondary interactions within the
RetGC1/GCAP1 complex.
Our NMR and mutagenesis data indicate that some residues
in EF1 of GCAP1 undergo a conformational change that
controls activation of RetGC. Although GCAP1 does not exhibit
a large main-chain conformational change like in recoverin,
GCAP1 residues in EF1 (K23, T27, G32) and EF4 show
Figure 6.  Schematic model of conformational changes in GCAP1 caused by Ca2+-binding at EF4.  (A) Structural model of
EF4mut activator state was generated by homology modeling using the NMR structure of recoverin (1jsa) that contains Ca2+ bound
at EF2 and EF3 [23]. The four EF-hands are colored green (EF1), red (EF2), cyan (EF3) and yellow (EF4), and bound Ca2+ is
orange. (B) The crystal structure of Ca2+-saturated GCAP1 (2r2i) shows key hydrophobic residues at the domain interface are
solvent exposed in the Ca2+-bound inhibitor state. The Ca2+-dependent rearrangement of the W94 side-chain at the domain interface
might control the switching between activator and inhibitor states. The N-terminal myristoyl group (magenta) is sequestered inside
the protein in both structures.
doi: 10.1371/journal.pone.0081822.g006
Conformation of GCAP1 Activator State
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relatively large backbone chemical shift differences between
Ca2+-saturated GCAP1 and EF4mut (Figure 4). Mutagenesis of
some EF1 residues (K23D and G32N) shows relatively large
effects on RetGC activation and binding (Table 1). The
decreased affinity for cyclase binding by both mutants should
prevent their binding to the cyclase under in vivo conditions,
because the estimated concentration of GCAPs and RetGC
isozymes in the rod outer segment does not exceed 10 μM
[52,53].
Previous studies have implicated EF1 as a possible binding
site for the cyclase [14,35,54,55]. Indeed, our observation in
this study that Ca2+-binding at EF4 can remotely affect the
structure of EF1 is consistent with the recently proposed Ca2+-
myristoyl tug mechanism [56]. The binding of either Mg2+ or
Ca2+ to EF2 and EF3 is sufficient for GCAP1 binding to RetGC1
[42] and promoting the proper conformation of GCAP1 in the
activator state [12]. Therefore, Ca2+ binding to EF4 is the main
determinant that switches GCAP1 from activator to inhibitor
state. It is possible that Ca2+-binding to EF4 causes local
structural changes in EF4 (see large CSD values for EF4
residues in Figure 4) that can be transmitted to EF1 through
the N-terminal myristoyl group and C-terminal helix in GCAP1
(residues M165 – Q187). Indeed, assigned residues in the C-
terminal helix (L176, T177, I179) exhibit large CSD values
(Figure 4A) and are conformationally dynamic (Figure 3B).
Thus, the structural link between the myristoyl group and both
EF1 and the C-terminal helix may serve as a lever that
connects the observed conformational changes in EF1 and
EF4 (Figure 4).
Several studies suggest a possible role for EF1 in forming
the RetGC1 binding interface. Point mutations of several EF1
residues in GCAP2 can suppress its ability to bind and activate
RetGC1 [35], and deletion of the conserved Cys and Pro in the
EF1 loop also suppresses GCAP1’s ability to stimulate RetGC1
[34]. The replacement of the EF1 domain in GCAP2 or GCAP1
with that of recoverin or neurocalcin eliminates their ability to
activate the cyclase [14,54]. However, the structural
determinants and dynamics in EF1 that control the activator-to-
inhibitor transition of GCAP1 are still poorly understood and will
require further investigation.
GCAP residues in EF2 and EF3 located at the domain
interface (V77 – W94, see Figures 1 and 6) appear to be
another “hot spot” for controling activation of RetGC [14,54].
GCAP1 residues at the domain interface have quite broad
NMR resonances that are temperature sensitive. The
corresponding residues in recoverin (Figure 1) also exhibited
broad NMR resonances and 15N NMR relaxation dispersion
studies reveal that these domain interface residues are
conformationally dynamic [39]. Ca2+-induced rearrangement of
residues at the domain interface in recoverin gives rise to a 45
degree swiveling of the two domains [23]. Our homology model
of EF4mut suggests a related but much smaller Ca2+-induced
structural change at the domain interface in GCAP1 (Figure 6).
The most noteworthy Ca2+-induced structural difference in
GCAP1 can be seen in the entering helix of EF3 that unravels
a half turn in EF4mut, which causes a repositioning of the W94
side-chain at the domain interface. A Ca2+-induced change in
the structural environment around W94 is consistent with
previous tryptophan fluorescence and electron paramagnetic
resonance studies of GCAP1 [12,19,57]; however, mutations of
W94 do not significantly alter the Ca2+-binding affinity of
GCAP1 [12]. We suggest that exposure of W94 indole side-
chain in the GCAP1 activator state might play a role in
contacting RetGC1.
Other hydrophobic residues at the GCAP1 domain interface
(V77, A78, L82) remain solvent exposed in both the EF4mut
(Figure 6A) and Ca2+-saturated crystal structure (Figure 6B).
The exposure of these hydrophobic residues might mediate
specific contacts with RetGC and/or control GCAP1
dimerization. Indeed, mutagenesis of GCAP1 residues at the
domain interface both disrupts GCAP1 dimerization (Figure 3C)
and abolishes activation of the cyclase (Table 1). Future
studies are needed to better understand how residues at the
domain interface control GCAP1 dimerization and/or modulate
interactions with RetGC.
The structure and dynamics of the important C-terminal
region of GCAP1 (residues 170 - 175) could not be examined
in our study, because most of the NMR resonances in this
region were exchange broadened. In GCAP2, Ca2+ binding
makes its C-terminal phosphorylation site more accessible for
cGMP-dependent kinase [58]. However, we presently cannot
draw any conclusion about the structural dynamics of residues,
L170-D175 in GCAP1, because there is no such
phosphorylation site in GCAP1. Also, we could not determine
CSD values for these residues due to the broadening of NMR
resonances in this region for both the activator and inhibitor
states.
One of the most important outstanding questions for
understanding GCAP structure-function relationships is to
determine the location of the cyclase binding site in the
GCAPs. Previous studies [14,35,54] and the current study
indicate three possible regions in GCAPs that control their
ability to activate RetGC: EF1, the interface between EF2 and
EF3, and the C-terminal region adjacent to EF4. The CSD
detected by NMR spectroscopy reveal conformational changes
related to some of these residues in GCAP1. Importantly, most
of the conformational changes observed in this study for
EF4mut may be similar to those caused by a mutation, E155G,
triggering congenital retinal dystrophy in human patients. This
mutation also prevents Ca2+ binding to EF4 and, by
constitutively activating RetGC1, produces excessive
accumulation of cGMP and Ca2+ in photoreceptors thus
causing their apoptotic death [20,38]. Moreover, many other
mutations cause congential human blindness by affecting Ca2+
binding to EF4 [41,59–61]. Therefore, the use of CSD in
EF4mut as a model provides a useful tool for evaluating the
structural changes in GCAP1 upon its conversion into the
constitutively active state.
However, CSD alone is not sufficient to identify specific
residues that make direct contact with the cyclase, because the
CSD does not discriminate between backbone changes caused
by the Ca2+ sensor action versus backbone changes required
to accommodate RetGC1 binding. Some of the residues (e.g.
K23 and G32 in EF1) display CSD that may reflect their
potential involvement in the cyclase binding interface.
However, for most residues that exhibited large CSD,
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mutations altering the properties of the side chain did not
abolish cyclase activation (Table 1). Hence, the most
prominent CSD observed for residues in EF3 and EF4 (which
are still rather small compared to the CSD observed in
recoverin) may simply reflect localized metal-dependent
conformational changes that occur outside the cyclase-binding
site. Thus, the mapping of the cyclase-binding site in GCAP1
cannot be derived from the CSD alone. A comprehensive
mutagenesis of exposed surface residues in GCAP1 is
currently under way to pinpoint those residues mapped onto
the GCAP1 structure (Figure 6) that are directly involved in
forming the cyclase-binding interface.
Materials and Methods
Expression and purification of GCAP1 and mutants
Mutations were introduced in a bovine GCAP1 coding
plasmid using a “splice by overlap extension” approach as
previously described [11]. Myristoylated GCAP1 and its
mutants were produced in E. coli strain harboring yeast N-
myristoyl transferase and purified to homogeneity using
previously described method [12]. The expression and
purification of isotopically labeled GCAP1 and mutants were
described previously [28]. Uniformly 15N-labeled GCAP1, 15N-
labeled EF4mut, and triple labeled 2H/15N/13C-labled EF4-mut
used in the NMR studies (0.5 mM) were dissolved in 5 mM
Tris-d11 (pH 7.4), 5 mM CaCl2, 5 mM MgCl2, 5 mM dithiothreitol-
d10, 40 mM octyl-β-D-gluco-pyranoside and 93%/7% H2O/D2O.
Guanylyl cyclase assay
Recombinant human RetGC1 was expressed in HEK293
cells and assayed in vitro using [α-32P] GTP as a substrate as
previously described in detail [12,56]. Ca/Mg/ethylene glycol
tetraacetic acid buffers for the assay were prepared and
calibrated as previously described [12].
NMR spectroscopy
NMR experiments and backbone assignments for Ca2+-
saturated GCAP1 were described elsewhere [31]. Backbone
NMR resonance assignments of the EF4mut activator state
(Ca2+ bound at EF2 and EF3) were obtained in this study by the
analysis of three-dimensional NMR data as described
previously [62]. 2D 15N-1H HSQC with 2048 (1H) x 256 (15N)
data points, 3D HNCACB with1024 (1H) x 64 (15N) x 120 (13C)
data points, and 3D HNCO with 2048 (1H) x 64 (15N) x 128 (13C)
data points were all performed on a triple-labeled EF4mut
sample using 800 MHz Bruker NMR spectrometer equipped
with a triple resonance cryogenic probe. In addition, 3D
HNCOCACB with 1024 (1H) x 64 (15N) x 128 (13C) data points
was performed on the triple-lableled sample using a 600 MHz
Bruker NMR spectrometer, equipped with a triple resonance
cryogenic probe. All NMR experiments were performed at 37
°C. Spectra were processed using NMRPipe software package
[63] and analyzed using SPARKY.
15N NMR relaxation analysis
15N NMR longitudinal relaxation rates (R1) and transverse
relaxation rates (R2) of Ca2+-saturated GCAP1 and EF4mut
were measured using pulse schemes described previously at
60.81 MHz 15N resonance frequency [64]. Relaxation delays for
R1 experiments were 0.01, 0.25, 0.5, 1.0 and 2.0 s. Relaxation
delays for R2 experiments were 8, 16, 24, 32, 48, 64 and 80
ms. The 180° pulses for Car-Purcell-Meiboom-Gill (CPMG)
sequence were applied every 1.0 ms. Uncertainty of R1 and R2
values were determined by Monte-Carlo error simulation using
signal intensities that contain experimental noise fluctuation.
Model-free parameters including generalized order parameters
and correlation times for internal motion [65–67] were
determined using the protocol described previously [64].
Size exclusion chromatography and multi-angle light
scattering
Determination of the molar mass of GCAP1 was carried out
using a multi-angle light scattering instrument (Wyatt
Technologies Inc. TREOS and Optlab Rex) coupled to a
Superdex 200 HR 10/30 column (Amersham) at 4 °C
equilibrated in buffers containing either 10 mM phosphate (pH
7.0) or 10 mM acetate (pH 4.5). A 0.1 ml aliquot of protein (200
μM) was loaded onto the column and eluted at a flow rate of
0.5 ml/min. The molar mass of the eluted protein was
calculated from the observed light scattering intensity as
described previously [68]. Apparent molecular weights were
also calculated using a standard curve of Ve/Vo versus the log
of the molecular weights of standard proteins: β-amylase (200
kDa), alcohol dehydrogenase (150 kDa), carbonic anhydrase
(29 kDa), and cytochrome c (12.4 kDa). Vo is a void volume
obtained using blue dextrane (2000 kDa) and Ve is a volume of
elution.
Homology model structure calculation
To generate a homology modeled structure of GCAP1 with
Ca2+ bound at EF2 and EF3, we first used the NMR structure of
Ca2+-bound recoverin (1JSA) that contains Ca2+ bound at EF2
and EF3 as a template in the modeler software, Swiss-Model
[69]. The resulting homology modeled structure contained an
extruded myristoyl group, which disagrees with the myristoyl
group being sequestered inside GCAP1 in both the activator
and inhibitor states [28]. Therefore, we replaced the N-terminal
domain of the homology modeled structure (residues 2-87) with
the structure of the corresponding residues from the GCAP1
crystal structure (2R2I) that contains a sequestered myristoyl
group. The main chain atoms of the N-terminal domain from
the GCAP1 crystal structure (residues 2-87) were
superimposed onto the corresponding atoms in the homology
modeled structure using the software, Chimera. This alignment
procedure positioned the N-terminal domain of the GCAP1
crystal structure in close proximity to the C-terminal domain of
the homology modeled structure (Ca2+ bound at EF3 and not
bound at EF4). The last residue of the overlaid N-terminal
domain (K87) was covalently attached to residue V88 from the
homology modeled structure (using the patch command in
Chimera), which effectively connected the N-terminal domain of
2R2I with the C-terminal domain generated by homology
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modeling. The resulting structure contained a sequestered
myristoyl group with Ca2+ bound at EF2 and EF3. The entire
modeled structure was energy minimized using Xplor-NIH.
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